410 total citations 12 papers, 317 citations indexed
About
Eggermont Am is a scholar working on Oncology, Immunology and Molecular Biology.
According to data from OpenAlex, Eggermont Am has authored 12 papers receiving a total of 317 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Immunology and 4 papers in Molecular Biology. Recurrent topics in Eggermont Am's work include Cutaneous Melanoma Detection and Management (6 papers), Immune Cell Function and Interaction (4 papers) and Melanoma and MAPK Pathways (3 papers). Eggermont Am is often cited by papers focused on Cutaneous Melanoma Detection and Management (6 papers), Immune Cell Function and Interaction (4 papers) and Melanoma and MAPK Pathways (3 papers). Eggermont Am collaborates with scholars based in Netherlands and United States. Eggermont Am's co-authors include Kroon Bb, Philippe Autier, D. Liénard, F. Rosenkaimer, Sugarbaker Ph, J Jeekel, Ulrich Keilholz, Axel Hauschild, M. Gore and Paul Lorigan and has published in prestigious journals such as The Lancet, British Journal of Cancer and PubMed.
In The Last Decade
Eggermont Am
12 papers
receiving
311 citations
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Eggermont Am's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eggermont Am with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eggermont Am more than expected).
This network shows the impact of papers produced by Eggermont Am. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eggermont Am. The network helps show where Eggermont Am may publish in the future.
Co-authorship network of co-authors of Eggermont Am
This figure shows the co-authorship network connecting the top 25 collaborators of Eggermont Am.
A scholar is included among the top collaborators of Eggermont Am based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Eggermont Am. Eggermont Am is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
12 of 12 papers shown
1.
Am, Eggermont, Stefan Suciu, Mario Santinami, et al.. (2008). EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.. The Lancet. 12. 117–126.77 indexed citations
2.
Keilholz, Ulrich & Eggermont Am. (2000). The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program.. PubMed. 6 Suppl 1. S99–103.11 indexed citations
3.
Am, Eggermont, et al.. (1997). Regional application of TNF alpha in the treatment of cancer: a preclinical-clinical interactive program.. PubMed. 47(1-2). 104–13.11 indexed citations
4.
Bb, Kroon, et al.. (1994). Is there an indication for a double perfusion schedule with melphalan for patients with recurrent melanoma of the limbs?. PubMed. 4 Suppl 1. 13–6.6 indexed citations
5.
Bb, Kroon, et al.. (1994). Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion.. PubMed. 178(6). 564–72.49 indexed citations
6.
Liénard, D., et al.. (1994). Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study.. PubMed. 4 Suppl 1. 21–6.84 indexed citations
7.
Bb, Kroon, et al.. (1993). Regional isolated perfusion with melphalan for patients with subungual melanoma.. PubMed. 19(1). 37–42.5 indexed citations
8.
Stoter, G., et al.. (1992). Treatment of disseminated renal cell cancer with combinations of interleukin-2, lymphokine-activated killer cells, and alpha-interferon.. PubMed. 378. 225–33.2 indexed citations
9.
Am, Eggermont & Sugarbaker Ph. (1989). Efficacy of intracavitary administration of cyclophosphamide, interleukin-2 and lymphokine activated killer cells against established intraperitoneal tumor.. PubMed. 16(3-4). 47–50.2 indexed citations
10.
Am, Eggermont, et al.. (1988). Local regional promotion of tumor growth after abdominal surgery is dominant over immunotherapy with interleukin-2 and lymphokine activated killer cells.. PubMed. 12(1-6). 421–9.49 indexed citations
Am, Eggermont, et al.. (1985). Phase II trial of high-dose recombinant leukocyte alpha-2 interferon for metastatic colorectal cancer without previous systemic treatment.. PubMed. 69(2). 185–7.12 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.